On December 15, 2017 Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, reported that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI) (Press release, Endocyte, DEC 15, 2017, View Source [SID1234522667]). Endocyte’s addition to the NBI will become effective prior to market open on Monday, Dec, 18, 2017.

The NASDAQ Biotechnology Index (NBI) contains securities of NASDAQ-listed companies that meet certain eligibility criteria, and are classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals. These requirements include minimum market capitalization, and average daily trading volume. For more information about the NASDAQ Biotechnology Index visit View Source